## NDAQ: Nasdaq, Inc. - XLF: Financial Services

### Executive Summary

STRENGTH thesis confirmed: MRS_10 at 3.2% in lower entry zone (3.0-6.0%), top 9% cross-sectional ranking. Short-term MRS_5 (1.4%) confirms momentum alignment. Caution: overbought RSI (76).

- **Horizon:** 5-20 days (swing)
- **Risk Profile:** Moderate - momentum continuation
- **Stop Type:** Fixed 2xATR ($94.08)
- **If Wrong:** Exit if MRS_10 drops below entry zone or breaks stop
- **Invalidation:** MRS_10 exits entry zone or MRS_5 turns negative

### News

- **Articles:** 10
- **Sentiment:** Neutral (Bullish: 0, Bearish: 0)

**1. Lobo EV Technologies stock falls after Nasdaq compliance warning**
- Source: Investing.com India | 20251220T071016 | Somewhat-Bearish | Relevance: 73%
- Lobo EV Technologies Ltd (NASDAQ:LOBO) stock dropped 4.8% after-hours following a Nasdaq non-compliance notice. The company failed to meet the minimum bid price requirement of $1.00 per share for 30 consecutive business days. LOBO has until June 15, 2026, to regain compliance and stated it would explore all options, including a potential reverse stock split.

**2. Guarantor: JPMorgan Chase & Co.**
- Source: StreetInsider | 20251222T180307 | Neutral | Relevance: 70%
- This document outlines the terms for JPMorgan Chase Financial Company LLC's structured investments consisting of $240,000 notes linked to the least performing of the Dow Jones Industrial Average, Nasdaq-100 Index, and Russell 2000 Index, due June 22, 2029. JPMorgan Chase & Co. fully and unconditionally guarantees these notes. The notes are designed for investors seeking exposure to the appreciation of these indices, with a minimum repayment of 95.00% of their principal at maturity.

**3. OKYO Pharma management to ring Nasdaq opening bell in New York**
- Source: Investing.com | 20251220T120848 | Somewhat-Bullish | Relevance: 65%
- OKYO Pharma Ltd (NASDAQ:OKYO) announced that its Executive Chairman and Founder, Gabriele Cerrone, along with the management team, will ring the Opening Bell at the Nasdaq MarketSite in Times Square, New York, on Friday, from 9:15 AM to 9:30 AM Eastern Time. This event recognizes the company's work in developing new treatments, specifically its lead candidate, urcosimod, for neuropathic corneal pain. The company is headquartered in London and listed on Nasdaq.

**4. Seagate Technology Holdings plc (STX) Stock: Nasdaq-100 Inclusion, Latest News, Analyst Forecasts, and What’s Next (Dec. 22, 2025)**
- Source: ts2.tech | 20251222T164501 | Neutral | Relevance: 64%
- Seagate Technology Holdings plc (STX) officially joined the Nasdaq-100 Index on December 22, 2025, a move expected to boost visibility and institutional demand despite an initial dip in stock price. The company's performance in 2025 has been driven by surging "AI infrastructure" beneficiaries and data-center storage demand. Upcoming catalysts include its fiscal Q2 2026 earnings report expected in late January 2026, guidance on its Mozaic HAMR products, and an upcoming dividend payment on January 9, 2026.

**5. |First Financial Northwest, Inc. Announces Closing of Acquisition of First Financial Northwest Bank by Global Federal Credit Union**
- Source: TradingView — Track All Markets | 20251222T020940 | Neutral | Relevance: 64%
- |First Financial Northwest, Inc. announced the closing of its acquisition by Global Federal Credit Union, effective April 11, 2025. The company received $228.7 million in cash and will delist its shares from Nasdaq by April 21, 2025. First Financial Northwest plans to distribute its remaining assets to shareholders in upcoming distributions before dissolving.

### Analyst Activity

**Target Signal:** NEUTRAL (Raises: 2, Lowers: 0)

| Date | Firm | Target | Prior | Change |
|------|------|--------|-------|--------|
| 2025-12-22 | Morgan Stanley | $111 | $110 | +1% |
| 2025-12-12 | Barclays | $114 | $109 | +5% |

**Rating Changes:**

| Date | Firm | Action | Grade |
|------|------|--------|-------|
| 2025-12-22 | Morgan Stanley | main | Overweight |
| 2025-12-12 | Barclays | main | Overweight |

### Insider Activity (90 days)

| Metric | Value |
|--------|-------|
| Direction | **NET_SELLING** |
| Buys | 0 ($0.00M) |
| Sells | 6 ($2.76M) |

### Institutional Ownership

| Metric | Value |
|--------|-------|
| Total Ownership | 49.0% |
| Smart Money | **BEARISH** |
| Net Flow | 0.0% |
| Buying/Selling | 4 / 5 |

**Top Holders:**
- Vanguard Group Inc: 10.4% (+6.9%)
- Investor AB: 10.2% (0.0%)
- Blackrock Inc.: 7.0% (+8.3%)
- Wellington Managemen: 7.0% (-3.5%)
- Massachusetts Financ: 4.6% (-3.3%)

### Key Risks

1. Market regime shift could impact momentum names disproportionately.
2. Sector rotation risk if leadership changes from current market theme.
3. Earnings execution risk on next quarterly report.

### Catalysts

- M&A activity or partnership announcements may unlock value.
- Broader market risk-on sentiment could lift quality names.

### Fundamentals

PEG ratio 1.46 suggests fair value with growth premium. Forward P/E 25.5x stretched relative to 11% growth. Quality metrics strong (margin 20%). Insider selling cluster ($2.8M in 90 days), potential headwind. Institutional flow bearish (5 selling vs 4 buying).

| Metric | Value |
|--------|-------|
| Market Cap | $55.9B |
| Beta | 1.02 |
| 52W Range | $64.84 - $97.72 |
| Short Interest | 1.4% |

| Valuation | Value |
|-----------|-------|
| PEG Ratio | 1.46 |
| Forward P/E | 25.5 |
| Current P/E | 28.4 |
| YoY Growth | 11.5% |
| EPS Direction | STABLE |

### Technicals

MRS_10 stable at 3.2% (minimal 5-day change). Currently in lower STRENGTH zone (3.0-6.0%), cross-sectional ranking at 91st percentile. MRS_5 at 1.4% confirms short-term momentum alignment. Full SMA alignment bullish (above 20/50/200 SMAs). MACD histogram positive (0.56), confirming momentum. RSI overbought at 76, risk of mean reversion. OFD pattern: +MTN (Rally).

| Metric | Value | Signal |
|--------|-------|--------|
| MRS_10 | 3.24% (CS: 91) | Strong |
| RSI_14 | 76.2 | Overbought |
| MACD Histogram | 0.56 | Bullish |
| vs SMA20 | 1.064x | Above |
| vs SMA50 | 1.093x | Above |
| vs SMA200 | 1.130x | Above |

### Decision

- **Verdict:** AVOID
- **Thesis:** STRENGTH

### Trade Setup

- **Entry:** $97.46
- **Stop Loss:** $94.08 (3.5% risk)
- **Target:** $102.53 (R:R method)
- **Risk/Reward:** 1.50:1
- **Target Reasoning:** STRENGTH thesis targets 1.5x risk/reward based on historical edge

### Position Sizing

- **Shares:** 266
- **Position Value:** $25,924.36
- **Portfolio %:** 25.92%
- **Risk Dollars:** $900.00
- **Risk Per Trade:** 0.90%
- **Modifiers:** L1 120% | L2 75% | Combined 0.90x

### Market Context

| Layer | Signal | Modifier |
|-------|--------|----------|
| L1 Macro | NORMAL (MEDIUM) | 1.20x |
| L2 Sector | WEAKENING (Zone B) | 0.75x |

*NORMAL regime with improving risk appetite. VIX decline to 52-week lows and moderate breadth recovery suggest calming conditions, though narrow participation indicates selectivity remains key. Positive earnings momentum and AI adoption themes provide fundamental support for quality growth names.*

### Earnings

**Next:** 2026-01-28 (Est: $0.91)

| Quarter | Est | Actual | Surprise |
|---------|-----|--------|----------|
| 2025Q3 | $0.85 | $0.88 | +3.7% |
| 2025Q2 | $0.81 | $0.85 | +4.6% |
| 2025Q1 | $0.77 | $0.79 | +2.5% |
| 2024Q4 | $0.75 | $0.76 | +1.4% |

---
*RULE-based L3 | 2026-01-06 16:38 | MRS_10*